Key Insights on Gross Profit: Takeda Pharmaceutical Company Limited vs Jazz Pharmaceuticals plc

Takeda vs Jazz: A Decade of Gross Profit Insights

__timestampJazz Pharmaceuticals plcTakeda Pharmaceutical Company Limited
Wednesday, January 1, 201410554570001256834000000
Thursday, January 1, 201512222770001271973000000
Friday, January 1, 201613825870001173296000000
Sunday, January 1, 201715085050001274610000000
Monday, January 1, 201817693780001437534000000
Tuesday, January 1, 201920338310002201424000000
Wednesday, January 1, 202022146500002203504000000
Friday, January 1, 202126534780002462160000000
Saturday, January 1, 202231188570002783406000000
Sunday, January 1, 202333986270002832257000000
Monday, January 1, 20242832257000000
Loading chart...

Unleashing insights

A Tale of Two Pharmaceuticals: Gross Profit Trends from 2014 to 2023

In the competitive world of pharmaceuticals, financial performance is a key indicator of success. Over the past decade, Takeda Pharmaceutical Company Limited and Jazz Pharmaceuticals plc have shown distinct trajectories in their gross profit margins. Takeda, a Japanese giant, consistently outperformed Jazz, with gross profits peaking at approximately ¥2.8 trillion in 2023, marking a 125% increase from 2014. Meanwhile, Jazz, a smaller player, demonstrated impressive growth, with gross profits rising by over 220% to reach $3.4 billion in the same period. This stark contrast highlights Takeda's dominance in scale, while Jazz showcases agility and rapid growth. Notably, data for 2024 is incomplete, leaving room for speculation on future trends. As the pharmaceutical landscape evolves, these insights provide a glimpse into the strategic maneuvers of these industry leaders.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025